Business Context and Reporting Period
This Form 8-K Current Report was filed by Xeris Biopharma Holdings, Inc. on August 2, 2024, regarding events occurring on August 1, 2024. The filing primarily addresses a senior executive promotion and the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes
The material change reported is the promotion of Kevin McCulloch to President and Chief Operating Officer, effective August 1, 2024. Mr. McCulloch will report to CEO John Shannon. This promotion is accompanied by a new employment agreement with the following terms:
- Base Salary: $520,000 annually.
- Target Incentive: 50% of the annual base salary.
- Equity Grants:
- 150,000 Restricted Stock Units (RSUs) vesting ratably over three years.
- 200,000 Stock Appreciation Rights (SARs) vesting in full on the second anniversary.
Outlook, Risks, and Contingencies
The filing details significant severance and acceleration contingencies tied to the new employment agreement:
- Termination without Cause/Good Reason:
- Outside 12 months of a Change in Control: 1.25x (Base Salary + Target Incentive).
- Within 12 months of a Change in Control: 1.5x (Base Salary + Target Incentive).
- Additional Benefits upon Termination: Pro rata bonus, COBRA premium reimbursement for up to 15 months (or 18 months if within 12 months of a Change in Control), and up to three months of outplacement services if terminated within 12 months of a Change in Control.
- Acceleration: In the event of termination without cause or for good reason within 12 months of a Change in Control, all time-based stock options and awards will accelerate and vest immediately.
Investor Verification Checklist
- Verify the total potential cash and equity value of the new compensation package relative to the company's current cash position.
- Review the full text of the Second Amended and Restated Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Assess the impact of the 150,000 RSUs and 200,000 SARs on potential future dilution.
- Confirm the vesting schedules and service requirements for the new equity grants.